Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients with active relapsing-remitting MS (RRMS) (CARE-MS I; NCT00530348). METHODS: Alemtuzumab-treated patients received treatment courses at baseline and 12 months later; after the core study, they could enter an...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neurology
Auteurs principaux: Havrdova, Eva, Arnold, Douglas L., Cohen, Jeffrey A., Hartung, Hans-Peter, Fox, Edward J., Giovannoni, Gavin, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Jody, Darlene, Hogan, Richard J., Xenopoulos, Panos, Panzara, Michael A., Coles, Alasdair J.
Format: Artigo
Langue:Inglês
Publié: Lippincott Williams & Wilkins 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595278/
https://ncbi.nlm.nih.gov/pubmed/28835401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000004313
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires